Metagenomic next-generation sequencing unraveled the characteristic of lung microbiota in patients with checkpoint inhibitor pneumonitis: results from a prospective cohort study
Journal for ImmunoTherapy of Cancer · 2025
DOI: 10.1136/jitc-2025-012444 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Zhenhua Zhou und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Immune Checkpoint Inhibitors, Lung, Metagenomics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medical Scientific Research Foundation of Guangdong Province, Clinical Research Program of Nanfang Hospital Southern Medical University, President Foundation of Nanfang Hospital, Southern Medical University.
Abstract (Originalsprache)
Background
Checkpoint inhibitor pneumonitis (CIP) is among the most lethal immune-related adverse events in patients with cancer receiving immunotherapy. This study aims to characterize the lung microbiome in patients with CIP and evaluate its diagnostic potential.
Methods
In a prospective clinical trial ( NCT06192303 ), bronchoalveolar lavage fluid samples (BALF) were obtained from 38 patients presenting clinical symptoms and radiographic evidence of pneumonitis following immunotherapy. The cohort included 14 cases of pure-type CIP (PT-CIP), 14 cases of mixed-type CIP, and 10 cases of pulmonary infection (PI). Metagenomic next-generation sequencing (mNGS) of BALF was employed to delineate the lung microbiota profiles. Using linear discriminant analysis effect size, we discerned characteristic microbiota among the three groups and further explored the associations of signature microbiota with host immune-inflammatory markers. Functional enrichment analysis revealed potential metabolic reprogramming and differences in biological functions between patients with CIP and PI. Finally, leveraging four machine-learning models, we ascertained the clinical value of BALF microbiota profiles in diagnosing CIP.
Results
The composition of lung microbiota differed significantly between patients with CIP and PI. Microbial taxa, such as Porphyromonas , Candida , Peptostreptococcus , Treponema , and Talaromyces, exhibited distinct abundance patterns across the three groups. Correlation analysis revealed a significant positive relationship between Candida abundance and host immune-inflammatory markers, such as neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, monocyte-lymphocyte ratio, and systemic immune inflammation index. In contrast, Porphyromonas demonstrated a significant negative correlation. Compared with the patients with PT-CIP, the lung microbiota of patients with PI exhibited a more diverse biological and metabolic profile. Additionally, machine learning models based on BALF microbiota profiles could accurately diagnose CIP, with the decision tree model showing the best diagnostic performance (area under the curve: 0.88).
Conclusions
Our study represents the unique characterization of the lung microbiota profiles across distinct CIP subtypes and establishes a diagnostic model for CIP based on the decision tree. These findings emphasize the value of BALF mNGS in improving the diagnosis of CIP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
- Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
- Department of Nephrology, The Fourth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
- Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
- Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China liulaiyu@sina.com 1587258375@qq.com 171290466@qq.com.
Förderung
- Medical Scientific Research Foundation of Guangdong Province
- Clinical Research Program of Nanfang Hospital Southern Medical University
- President Foundation of Nanfang Hospital, Southern Medical University
- Natural Science Foundation of Guangdong Province
- National Natural Science Foundation of China
Zitieren
APA
Zhou, Z., Lin, J. R., Li, J., Huang, X., Yuan, L., Huang, J., Xie, W., Lu, J., Huang, W., He, S., Yu, D., Zhang, H., Ge, X., Li, M., Mao, Y., Yang, F., Cui, Z. K., Su, X., Zhan, Y., & Liu, L. (2025). Metagenomic next-generation sequencing unraveled the characteristic of lung microbiota in patients with checkpoint inhibitor pneumonitis: results from a prospective cohort study. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-012444
Vancouver
Zhou Z, Lin JR, Li J, Huang X, Yuan L, Huang J, et al. Metagenomic next-generation sequencing unraveled the characteristic of lung microbiota in patients with checkpoint inhibitor pneumonitis: results from a prospective cohort study. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2025-012444
BibTeX
@article{Zhou2025,
author = {Zhou, Zhenhua and Lin, Jia-Run and Li, Jiaxin and Huang, Xintong and Yuan, Lu and Huang, Jihong and Xie, Wenxia and Lu, Junyi and Huang, Wenqi and He, Shangwen and Yu, Dong and Zhang, Hailing and Ge, Xiaoyue and Li, Meihua and Mao, Yaqi and Yang, Fan and Cui, Zhong-Kai and Su, Xiaofang and Zhan, Yongzhong and Liu, Laiyu},
title = {Metagenomic next-generation sequencing unraveled the characteristic of lung microbiota in patients with checkpoint inhibitor pneumonitis: results from a prospective cohort study},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
doi = {10.1136/jitc-2025-012444}
}
EUVIMED